-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HSyYRqKI1ZVL6Ju75Kl/WJbQcmd4rN9qMbyKi5G14oh5lkiKDSdm9NNzplWvN5mp qDTbtkSyCN+TSfEEBI2rFw== 0000950134-07-004895.txt : 20070306 0000950134-07-004895.hdr.sgml : 20070306 20070306151201 ACCESSION NUMBER: 0000950134-07-004895 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070228 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20070306 DATE AS OF CHANGE: 20070306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADEZA BIOMEDICAL CORP CENTRAL INDEX KEY: 0000902482 STANDARD INDUSTRIAL CLASSIFICATION: INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825] IRS NUMBER: 770054952 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20703 FILM NUMBER: 07674548 BUSINESS ADDRESS: STREET 1: 1240 ELKO DR CITY: SUNNYVALE STATE: CA ZIP: 94089 8-K 1 f28063e8vk.htm FORM 8-K e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2007
Adeza Biomedical Corporation
(Exact name of registrant as specified in its charter)
000-20703
(Commission File Number)
     
Delaware
(State or other jurisdiction of
incorporation) 		  77-0054952
(I.R.S. Employer Identification No.)
1240 Elko Drive
Sunnyvale, California 94089
(Address of principal executive offices, with zip code)
(408) 745-0975
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On February 28, 2007, the Board of Directors (the “Board”) of Adeza Biomedical Corporation (the “Company”) approved increases to the base salaries for the Company’s named executive officers (as defined in Item 402 of Regulation S-K promulgated by the Securities and Exchange Commission). The Compensation Committee of the Board determines the annual salary adjustments of the Company’s named executive officers by evaluating the competitive marketplace, the performance of the Company, the performance of each executive and the operational areas of the Company for which that executive is responsible, and the responsibilities assumed by that executive. Each of the named executive officers received a merit increase in base salary, retroactive to February 1, 2007. The base salaries for the named executive officers retroactive to February 1, 2007, are as set forth across from each such officer’s name below:
             
        Base Salary Retroactive
Name   Title   to February 1, 2007
Emory V. Anderson
  President and Chief Executive Officer   $ 402,251  
Mark D. Fischer-Colbrie
  SVP, Finance and Administration and Chief Financial Officer   $ 280,027  
Durlin E. Hickok
  SVP, Medical Affairs   $ 276,203  
Marian E. Sacco
  SVP, Sales and Marketing   $ 280,399  
Robert O. Hussa
  Vice President, Research and Development   $ 215,955  

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ADEZA BIOMEDICAL CORPORATION
 		  
Date: March 6, 2007  By:   /s/ Mark D. Fischer-Colbrie    
    Mark D. Fischer-Colbrie   
    Chief Financial Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----